HALO * Stock Overview
A biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Halozyme Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$680.00 |
| 52 Week High | US$680.00 |
| 52 Week Low | US$680.00 |
| Beta | 1.25 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0.038% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| HALO * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 0.04% | 0% | 0% |
Return vs Industry: HALO * exceeded the MX Biotechs industry which returned -1.3% over the past year.
Return vs Market: HALO * underperformed the MX Market which returned 9.1% over the past year.
Price Volatility
| HALO * volatility | |
|---|---|
| HALO * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: HALO * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HALO *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 393 | Helen Torley | halozyme.com |
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.
Halozyme Therapeutics, Inc. Fundamentals Summary
| HALO * fundamental statistics | |
|---|---|
| Market cap | Mex$88.79b |
| Earnings (TTM) | Mex$4.33b |
| Revenue (TTM) | Mex$13.33b |
20.5x
P/E Ratio6.7x
P/S RatioIs HALO * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HALO * income statement (TTM) | |
|---|---|
| Revenue | US$780.71m |
| Cost of Revenue | US$259.78m |
| Gross Profit | US$520.93m |
| Other Expenses | US$267.03m |
| Earnings | US$253.91m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.92 |
| Gross Margin | 66.73% |
| Net Profit Margin | 32.52% |
| Debt/Equity Ratio | 601.0% |
How did HALO * perform over the long term?
See historical performance and comparison